Investigating inflammation and glutamate in depressed adolescents

Inflammatory and Glutamatergic Mechanisms of Sustained Threat in Adolescents With Depression: Toward Predictors of Treatment Response and Clinical Course

University of California, Los Angeles · NCT05329441

This study is testing how stress affects inflammation and a brain chemical in teenagers with depression to see if these factors can help predict how well they respond to common antidepressants over time.

Quick facts

Study typeObservational
Enrollment160 (estimated)
Ages14 Years to 21 Years
SexAll
SponsorUniversity of California, Los Angeles (other)
Locations1 site (Los Angeles, California)
Trial IDNCT05329441 on ClinicalTrials.gov

What this trial studies

This project aims to assess 160 treatment-seeking adolescents with depression to understand how acute stress affects inflammation and glutamate levels in the brain. The study will explore whether these biomarkers can predict treatment non-response to SSRIs like fluoxetine or escitalopram over a 12-week period, as well as their impact on the clinical course over 18 months. Using advanced neuroimaging techniques, the research seeks to uncover the neurobiological mechanisms linking inflammation and depression in adolescents.

Who should consider this trial

Good fit: Ideal candidates are adolescents aged 14-21 who meet DSM-V criteria for a depressive disorder and are currently seeking treatment.

Not a fit: Patients with primary mental health diagnoses other than depression or those currently on medications that interfere with the study will not benefit.

Why it matters

Potential benefit: If successful, this study could lead to improved treatment strategies for adolescents who do not respond to standard antidepressant therapies.

How similar studies have performed: While the study explores novel mechanisms, previous research has indicated that understanding inflammation's role in depression could lead to significant advancements in treatment.

Eligibility criteria

Show full inclusion / exclusion criteria
Inclusion Criteria:

* DSM-V criteria for a depressive disorder
* All sexes and genders
* All ethnicities
* Ages 14-21
* Postpubertal (Tanner stage \> 3)
* No medications that will interfere with the study (including antidepressants, mood stabilizers, hormone supplements, steroids, etc.) for at least 2-6 weeks (depending on exact medication)
* Currently being seen by a clinician who will treat the participant with fluoxetine or escitalopram
* The ability to provide assent, understand, and complete all study procedures
* Caregiver consent (if applicable)

Exclusion Criteria:

* Primary mental health diagnosis other than a depressive disorder according to DSM-V
* Any contraindications to MRI scanning, phlebotomy, or SSRI treatment
* Stimulant usage
* A concussion within the last 6 weeks or any lifetime concussion with loss of consciousness for at least 10 minutes
* Any inflammatory conditions or use of anti-inflammatory medications that may influence study findings
* Any major neurological or developmental disorders which could impact the participant's ability to comply with study procedure
* Meeting for current or lifetime criteria of mania or psychosis, diagnosis of bipolar disorder, or any substance use disorders
* First-degree relative with current, past, or suspected mania or psychosis

Where this trial is running

Los Angeles, California

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.

View on ClinicalTrials.gov →

Conditions: Depression in Adolescence, depression, adolescence

Last reviewed 2026-05-15 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.